Effect of a Chlorhexidine Gluconate-Based Oral Rinse Containing Natural Bioflavonoids on Soft Tissue Inflammation and...

This parallel-group clinical study evaluated whether adding natural bioflavonoids to 0.12% chlorhexidine (CHX) mouthwash enhances outcomes of non-surgical therapy for peri-implant mucositis. The primary aim was to assess soft-tissue inflammatory changes and subgingival Porphyromonas gingivalis (P. gingivalis) carriage compared with CHX alone.

Thirty-three patients were enrolled (test, n = 16; control, n = 17). All patients underwent mechanical debridement, following which patients in the test group were prescribed a bioflavonoid-enriched CHX, whereas those in the control group were prescribed 0.12% CHX. All participants were instructed to rinse their oral cavity every 12 hours for 30 s with their respective oral rinse for 3 weeks. A follow-up clinical evaluation was done after 6 weeks. Peri-implant indices, modified plaque index (mPI), modified bleeding index (mBI), and probing depth (PD) were recorded at baseline and follow-up. Subgingival oral biofilm samples were also collected and assessed for the presence of P.gingivalis in both groups. Statistical significance was set at P 0.05.

At baseline, groups were comparable across clinical parameters. At 6 weeks, the test group exhibited significantly lower mPI, mBI, and PD versus controls (all P 0.05). Specifically, mean PD was 2.2 ± 0.04 mm in the test group versus 2.5 ± 0.03 mm in controls; mPI and mBI also favoured the test rinse (0.38 ± 0.04 vs 0.30 ± 0.07; 0.28 ± 0.05 vs 0.32 ± 0.02, respectively). P. gingivalis was detected at baseline in all participants; at 6 weeks, carriage persisted in 3/16 (18.8%) test versus 9/17 (52.9%) control patients.

Supplementing 0.12% CHX with bioflavonoids provides added clinical benefits when used as an adjunct to mechanical debridement (MD) in patients with peri-implant mucositis. This combined approach appears more effective than 0.12% CHX alone in reducing peri-implant soft-tissue inflammation and P. gingivalis carriage, indicating that bioflavonoid-enriched formulations may represent a valuable therapeutic option in routine clinical practice for improving peri-implant health.